Assessment of serum afamin in patients with preeclampsia at third trimester

Abstract

Preeclampsia (PE) is a multisystem disorder associated with pregnancy. It is accompanied by a ten percent global neonatal and perinatal mortality rate. Human afamin (AFM) is a glycoprotein which bind vitamin E. It is primarily developed by hepatocytes in the liver and then secreted into the blood. Elevated serum afamin levels have been reported in hypertensive pregnancy complications such as Pregnancy Induced Hypertension (PIH). To evaluate afamin levels in preeclamptic women at third trimester and explore if there is any relation between Afamin and severity of preeclampsia, a case control study was performed in Chemistry and Biochemistry Department, College of Medicine, Al-Nahrain University, Baghdad, Iraq from July 2019 to March 2020. Forty-one patients and 30 participants in control group (normal pregnant women) joined this study. The preeclamptic and normal pregnancies were taken with cluster random sampling method. Afamin (AFM) levels were measured by enzyme-linked immune sorbent assay (ELISA).\xa0 Serum afamin (AFM) was significantly (p < 0.05) elevated in pregnant women with preeclampsia 2.34 ±0.23 (ng/mL) compared with that in normal pregnant women group 1.63± 0.19 (ng/mL). Although serum AFM concentration significantly increased in Preeclamptic women, there was no significant association differences between mild and sever groups.